Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development

This article was originally published in RPM Report

Executive Summary

Patient-reported outcomes in oncology clinical trials remain an infrequently used tool, despite acknowledgement by sponsors that the patient experience is important to measure – and encouragement from FDA officials to do so. The lack of PROs in oncology may be a byproduct of the fast pace of cancer drugs are developed in the U.S.: small trials and accelerated pathways.


Related Content

Medicare Advisers Endorse Patient Reported Outcomes For CAR-T With Caveats
Patient-Focused Guidance Writing: FDA Aiming For 'Sweet Spot' In Advice
Patient Voices Swayed FDA's Imlygic Review Team
FDA Outlines “Expedited” Review For Breakthrough Therapies; “Hyper-Fast” Reviews, Beyond Oncology
Patient-Reported Outcomes in Oncology: The Jakafi and Zytiga Exceptions
Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club
Adcetris Review Adds Some Clarity To Principles For Accelerated Approval


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts